A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Lung Cancer|Melanoma|Head and Neck Carcinoma|Gastroesophageal Cancer|Breast Cancer|Pancreatic Adenocarcinoma|Colorectal Cancer|Biliary Tract Cancer
Interventions: DRUG: Selumetinib|DRUG: MEDI4736|DRUG: Tremelimumab
Sponsor: AstraZeneca